300 likes | 412 Views
Treatment of HCV in Cirrhotic Patient. Mark Thursz. Mrs LG - Presentation. 48 year old Latvian woman HCV diagnosed 2007 – symptoms of fatigue Source of HCV unknown No alcohol No current medications No significant past medical history. Examination. Generally well
E N D
Treatment of HCV in Cirrhotic Patient Mark Thursz
Mrs LG - Presentation 48 year old Latvian woman HCV diagnosed 2007 – symptoms of fatigue Source of HCV unknown No alcohol No current medications No significant past medical history
Examination • Generally well • Palmarerythema and spider naevi • 4cm hepatomegaly • No splenomegaly • No ascites • No oedema • No encephalopathy
Initial investigations • Hb – 12.2 • WBC – 4.5 (Neutrophil 1.2) • Platelets – 75 • AFP – 18.3 • INR – 1.4 • Albumin – 32 • ALT – 73 • Bilirubin 18 • HCV RNA – 1,230,000 iu/ml • HCV Gt 1
Ultrasound • Irregular liver margin • Portal vein patent, diameter 17mm • No focal lesion • Spleen – 17.5 cm
Biopsy or not? • Fibroscan 38.5 kPa
OGD • Small varices • Propranolol 40mg tds • Not tolerated • Carvidolol 25 mg od
Summary • 48 year old woman • HCV cirrhosis (Child-Pugh A) • Portal hypertension • Low platelets and neutrophils • Treat now?
Treatment • Pegylated interferon a2a 180 ugo.w. • Ribavirin 600 mg b.d
Case Review • 49 year old woman • HCV Gt 1 • Relapse Responder • Portal hypertension • Low platelets • Low neutrophils • Options • Triple therapy • Await transplantation
Option 2 Telaprevir Pegasys Ribavirin Sinusitis Transfusion
Follow-up • USS every 6 Months • ? Biopsy in 5 years
Issues • Prognosis with decompensated cirrhosis – HCV • Impact of intervention with HCV • Potential drawbacks of HCV treatment • Benefits of treatment before transplant
Progression of Disease in HCV 7.7% 6.3% 3.7% 4.6% 9.9 – 20% 8.1 – 54.5% Alazawi. APT 2010
Survival in Decompensated HCV Cirrhosis 5 yr Survival - 50% Fattovich Gastro 1997
Issues • Prognosis with decompensated cirrhosis • Impact of intervention with HCV • Potential drawbacks of HCV treatment • Benefits of treatment before transplant
Treatment of HCV Cirrhosis Prevents Decompensation Bruno Hepatology 2007
Treatment of HCV Cirrhosis Reduces the Risk of HCC Bruno Hepatology 2007
Treatment of Decompensated HCV Cirrhosis Everson Hepatology 2005
Virological Outcomes According to Child’s Pugh Grade Everson Hepatology 2005
Issues • Prognosis with decompensated cirrhosis • Impact of intervention with HBV • Potential drawbacks of HBV treatment • Impact of intervention with HCV • Potential drawbacks of HCV treatment • Benefits of treatment before transplant
Issues • Prognosis with decompensated cirrhosis • Impact of intervention with HCV • Potential drawbacks of HCV treatment • Benefits of treatment before transplant
Reinfection post transplant Everson Hepatology 2005
Outcome of HCV Post-Transplant Gane NEJM 1996
Summary • Decompensated viral-cirrhosis has a poor prognosis • In HBV infection decompensation can be reversed with minimal side effects • In HCV infection treatment is challenging but the rewards are worth the effort • Decompensated cirrhotics cannot wait for IFN-free regimens • Eliminating HCV prior to transplantation will improve the prognosis
HCV Therapy Post-Transplant Vezali Clinical Therapeutics 2010